ST. LOUIS--(BUSINESS WIRE)--
Monsanto Company (MON) announced today that it has reached a global licensing agreement for the use of the CRISPR-Cas genome-editing technology in agriculture with the Broad Institute of MIT and Harvard.
The Broad Institute is a world leader in the development and sharing of CRISPR genome-editing technologies and holds several issued U.S. patents covering CRISPR-Cas technology. The parties, which share a broad-licensing philosophy to enable wide-ranging benefits from proprietary innovations, expect that this non-exclusive license agreement will deliver a wide array of crop improvements to global agriculture.
“The license to CRISPR-Cas from the Broad Institute provides access to an exciting tool for our growing body of genome-editing research,” said Tom Adams, Ph.D., biotechnology lead for Monsanto. “Genome-editing technology is complementary to our ongoing discovery research and provides an incredible resource to further unlock our world-leading germplasm and genome libraries.”
Under the agreement announced today, the Broad Institute grants Monsanto a worldwide non-exclusive license for agriculture applications of the CRISPR-Cas technology. Additional terms of the agreement were not disclosed.
“Genome-editing techniques present precise ways to dramatically improve the scale and discovery efficiency of new research that can improve human health and global agriculture,” said Issi Rozen, Chief Business Officer of the Broad Institute. “We are encouraged to see these tools being used to help deliver responsible solutions to help farmers meet the demands of our growing population.”
Genome-editing technologies present another key scientific tool that can deliver breakthroughs in agriculture. CRISPR-Cas works by making precisely-targeted modifications in a cell's DNA, similar to the search-and-replace function in modern-day word processing applications. Genome-editing technologies, such as CRISPR-Cas, offer a way for scientists to promote site-directed integration of specific genes as well as the opportunity to enhance beneficial or remove undesired plant characteristics. These techniques will enable plant breeders to deliver better hybrids and varieties more efficiently.
About Monsanto Company
Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops – such as corn, soybeans, and cotton – that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit: discover.monsanto.com and monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our News Release RSS Feed.
Cautionary Statements Regarding Forward-Looking Information
Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts, as well as the proposed transaction with Bayer Aktiengesellschaft (“Bayer”). These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: risks related to the proposed transaction between the company and Bayer, including the risk that the company’s shareowners do not approve the transaction, the risk that the regulatory approvals required for the transaction may not be obtained on the anticipated terms or time frame or at all, the risk that the other conditions to the completion of the transaction may not be satisfied, the risk that disruptions or uncertainties related to the proposed transaction could adversely affect the company’s business, financial performance and/or relationships with third parties, and the risk that certain contractual restrictions during the pendency of the transaction could adversely affect the company’s ability to pursue business opportunities or strategic transactions; continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public understanding and acceptance of our biotechnology and other agricultural products; the success of the company’s research and development activities; the outcomes of major lawsuits, including potential litigation related to the proposed transaction with Bayer; developments related to foreign currencies and economies; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the recent increases in levels of indebtedness, continued availability of capital and financing and rating agency actions; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters, accidents, and security breaches, including cybersecurity incidents, on the agriculture business or the company’s facilities; and other risks and factors detailed in the company’s most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.
For more information:
Last updated on: 23/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.